Process / pipelineClinical / epidemiology

Multicenter Phase I Clinical Trial

A multicenter Phase I clinical trial is the first systematic administration of an investigational agent to humans, conducted simultaneously across two or more clinical sites. Its primary objectives are to characterize the safety and tolerability profile of the intervention, determine the maximum tolerated dose (MTD), and describe pharmacokinetic and pharmacodynamic behavior. Distributing enrollment across sites increases participant accrual speed and enhances the generalizability of early-phase safety data.

Open in MethodMindSoonVideoSoon

Read the full method

Members only

Sign in with a free account to read this section.

Sign in

Sources

  1. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). (2016). ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). ICH. link
  2. Storer, B. E. (1989). Design and analysis of Phase I clinical trials. Biometrics, 45(3), 925-937. DOI: 10.2307/2531693

Related methods

Referenced by

ScholarGateMulticenter Phase I Clinical Trial (Multicenter Phase I Clinical Trial). Retrieved 2026-06-04 from https://scholargate.app/en/epidemiology/multicenter-phase-i-clinical-trial